Share on StockTwits

Synageva BioPharma Corp (NASDAQ:GEVA) released its earnings data on Friday. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.37) by $0.15, Analyst Ratings Network.com reports.

A number of research firms have recently commented on GEVA. Analysts at Janney Montgomery Scott reiterated a “fair value” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They now have a $111.00 price target on the stock, up previously from $107.00. On a related note, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They now have a $110.00 price target on the stock, down previously from $115.00. Finally, analysts at Citigroup Inc. initiated coverage on shares of Synageva BioPharma Corp in a research note on Tuesday, July 1st. They set a “neutral” rating and a $113.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Synageva BioPharma Corp presently has an average rating of “Buy” and a consensus target price of $109.11.

Synageva BioPharma Corp (NASDAQ:GEVA) opened at 68.41 on Friday. Synageva BioPharma Corp has a 52-week low of $44.52 and a 52-week high of $119.42. The stock’s 50-day moving average is $84.39 and its 200-day moving average is $87.75. The company’s market cap is $2.259 billion.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.